NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Cepheid's Xpert CT/NG test for marketing, the Sunnyvale, Calif.-based company announced after the close of the market on Thursday.

The test for the rapid detection and differentiation of chlamydia and Neisseria gonorrhoeae runs on Cepheid's GeneXpert system and allows for the same-day patient consultation and treatment of the two most common sexually transmitted bacterial infections in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.